These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11892915)

  • 1. VX-745. Vertex Pharmaceuticals.
    Haddad JJ
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1070-6. PubMed ID: 11892915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.
    Ding C
    Curr Opin Investig Drugs; 2006 Nov; 7(11):1020-5. PubMed ID: 17117592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38 MAP kinase inhibitors: many are made, but few are chosen.
    Dominguez C; Powers DA; Tamayo N
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):421-30. PubMed ID: 16022178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
    Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
    Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pralnacasan (vertex pharmaceuticals).
    Siegmund B; Zeitz M
    IDrugs; 2003 Feb; 6(2):154-8. PubMed ID: 12789619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
    Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
    J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.
    Alam J; Blackburn K; Patrick D
    J Prev Alzheimers Dis; 2017; 4(4):273-278. PubMed ID: 29181493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
    Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
    J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis.
    Pargellis C; Regan J
    Curr Opin Investig Drugs; 2003 May; 4(5):566-71. PubMed ID: 12833650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From imidazoles to pyrimidines: new inhibitors of cytokine release.
    Laufer SA; Wagner GK
    J Med Chem; 2002 Jun; 45(13):2733-40. PubMed ID: 12061876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCIO-469 Scios Inc.
    Nikas SN; Drosos AA
    Curr Opin Investig Drugs; 2004 Nov; 5(11):1205-12. PubMed ID: 15573872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gram-scale synthesis of the p38α MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome.
    Bagley MC; Davis T; Dix MC; Fusillo V; Pigeaux M; Rokicki MJ; Kipling D
    Future Med Chem; 2010 Sep; 2(9):1417-27. PubMed ID: 21426137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microwave-assisted Ullmann C-S bond formation: synthesis of the P38alpha MAPK clinical candidate VX-745.
    Bagley MC; Davis T; Dix MC; Fusillo V; Pigeaux M; Rokicki MJ; Kipling D
    J Org Chem; 2009 Nov; 74(21):8336-42. PubMed ID: 19778055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
    Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
    Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
    Kumar S; Votta BJ; Rieman DJ; Badger AM; Gowen M; Lee JC
    J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyridazine based inhibitors of p38 MAPK.
    McIntyre CJ; Ponticello GS; Liverton NJ; O'Keefe SJ; O'Neill EA; Pang M; Schwartz CD; Claremon DA
    Bioorg Med Chem Lett; 2002 Feb; 12(4):689-92. PubMed ID: 11844702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
    Kell J
    Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation.
    Kuliopulos A; Mohanlal R; Covic L
    Thromb Haemost; 2004 Dec; 92(6):1387-93. PubMed ID: 15583748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes.
    Natarajan SR; Doherty JB
    Curr Top Med Chem; 2005; 5(10):987-1003. PubMed ID: 16178742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
    Barone FC; Irving EA; Ray AM; Lee JC; Kassis S; Kumar S; Badger AM; White RF; McVey MJ; Legos JJ; Erhardt JA; Nelson AH; Ohlstein EH; Hunter AJ; Ward K; Smith BR; Adams JL; Parsons AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):312-21. PubMed ID: 11160612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.